Form 4: IRADIMED CEO Sells Shares Under 10b5-1 Plan

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock for approximately $484,000 through a pre-arranged trading plan.

Summary

• Roger E. Susi, who serves as CEO, President, and Chairman of IRADIMED Corp, reported the sale of 5,000 shares of the company's common stock.
• The transactions occurred on December 15, 2025.
• A total of 4,269 shares were sold at a weighted average price of $96.68 per share.
• An additional 731 shares were sold at a weighted average price of $97.13 per share.
• The total value of the shares sold is approximately $484,000.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Susi on June 16, 2025.
• Following these transactions, Mr. Susi's indirect beneficial ownership through the Phillip Susi 2008 Dynasty Trust decreased to 2,292,500 shares.
• Mr. Susi also indirectly beneficially owns 162,950 shares through the Roger E. Susi Revocable Trust and 2,062,500 shares through the Matthew Susi 2008 Dynasty Trust, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reports a pre-planned insider sale under a Rule 10b5-1 plan, which is a routine disclosure and not necessarily indicative of management's view on the company's future prospects or performance.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than a reaction to recent events or new material non-public information.

Negatives

• The CEO, President, and Chairman sold a total of 5,000 shares of common stock, which can sometimes be interpreted as a lack of confidence by some investors, despite being pre-planned.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.
• The reporting person undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

Industry Context

This insider transaction report does not provide information relevant to broader industry trends or competitive analysis.

Related Party Transactions

• Roger E. Susi, the CEO, President, and Chairman of IRADIMED Corp, sold 5,000 shares of the company's common stock.
• The shares were held indirectly through the Phillip Susi 2008 Dynasty Trust, a related entity.

Stakeholder Impact

• Shareholders may interpret insider selling differently; however, the existence of a Rule 10b5-1 plan often mitigates concerns that the sale is based on new, negative material non-public information.

Key Dates

Keywords

IRADIMED, IRMD, insider trading, Form 4, stock sale, CEO, 10b5-1 plan, beneficial ownership